Precipio, Inc. (PRPO)
PRPO Stock Price Chart
Explore Precipio, Inc. interactive price chart. Choose custom timeframes to analyze PRPO price movements and trends.
PRPO Company Profile
Discover essential business fundamentals and corporate details for Precipio, Inc. (PRPO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
30 Jun 2017
Employees
54.00
Website
https://www.precipiodx.comCEO
Ilan Danieli
Description
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO Financial Timeline
Browse a chronological timeline of Precipio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
Earnings released on 30 Mar 2026
EPS came in at $0.33 , while revenue for the quarter reached $7.97m .
Earnings released on 14 Nov 2025
EPS came in at -$0.05 falling short of the estimated $0.74 by -106.76%, while revenue for the quarter reached $6.77m , missing expectations by -15.54%.
Earnings released on 13 Aug 2025
EPS came in at $0.05 falling short of the estimated $0.74 by -93.24%, while revenue for the quarter reached $5.65m , missing expectations by -29.43%.
Earnings released on 14 May 2025
EPS came in at -$0.59 falling short of the estimated $0.40 by -247.50%, while revenue for the quarter reached $4.26m , missing expectations by -41.64%.
Earnings released on 27 Mar 2025
EPS came in at -$0.23 falling short of the estimated $0.74 by -131.08%.
Earnings released on 6 Nov 2024
EPS came in at -$0.42 falling short of the estimated $0.40 by -205.00%, while revenue for the quarter reached $5.21m , missing expectations by -28.59%.
Earnings released on 13 Aug 2024
EPS came in at -$0.83 falling short of the estimated -$0.05 by -1.56k%, while revenue for the quarter reached $4.44m , beating expectations by +2.59%.
Earnings released on 14 May 2024
EPS came in at -$1.46 falling short of the estimated -$0.93 by -56.99%, while revenue for the quarter reached $3.43m , missing expectations by -20.72%.
Earnings released on 29 Mar 2024
EPS came in at -$0.41 surpassing the estimated -$0.93 by +55.91%, while revenue for the quarter reached $4.33m , missing expectations by -0.71%.
Earnings released on 13 Nov 2023
EPS came in at -$1.04 surpassing the estimated -$1.21 by +14.05%, while revenue for the quarter reached $3.74m , missing expectations by -23.71%.
Stock split effective on 22 Sept 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2023
EPS came in at -$1.80 falling short of the estimated -$0.10 by -1.70k%, while revenue for the quarter reached $3.53m , beating expectations by +30.85%.
Earnings released on 12 May 2023
EPS came in at -$2.60 falling short of the estimated -$0.13 by -1.90k%, while revenue for the quarter reached $2.82m , beating expectations by +270.66%.
Earnings released on 30 Mar 2023
EPS came in at -$2.00 falling short of the estimated $0.14 by -1.53k%, while revenue for the quarter reached $2.39m , beating expectations by +19.55%.
Earnings released on 10 Nov 2022
EPS came in at -$2.80 falling short of the estimated -$0.80 by -250.00%, while revenue for the quarter reached $2.22m , missing expectations by -55.68%.
Earnings released on 11 Aug 2022
EPS came in at -$1.80 matching the estimated -$1.80, while revenue for the quarter reached $2.36m , meeting expectations.
Earnings released on 11 May 2022
EPS came in at -$4.00 falling short of the estimated -$1.00 by -300.00%, while revenue for the quarter reached $2.45m , missing expectations by -49.08%.
Earnings released on 30 Mar 2022
EPS came in at -$1.80 , while revenue for the quarter reached $2.44m .
Earnings released on 12 Nov 2021
EPS came in at -$1.60 , while revenue for the quarter reached $2.25m .
Earnings released on 12 Aug 2021
EPS came in at -$2.80 falling short of the estimated -$0.10 by -2.70k%, while revenue for the quarter reached $2.34m , meeting expectations.
PRPO Stock Performance
Access detailed PRPO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
